Wall Street Zen Upgrades Zimmer Biomet (NYSE:ZBH) to "Buy"

Key Points

• Wall Street Zen upgraded Zimmer Biomet to “Buy” from “Hold,” although the broader analyst consensus remains “Hold,” with seven Buy ratings, 15 Holds, one Sell, and a $104.47 consensus price target.
• Zimmer Biomet shares opened at $94.54 and were reported down 3.0%; the company has a market capitalization of approximately $18.03 billion and trades at a P/E ratio of 23.0.
• The company exceeded quarterly expectations, reporting $2.07 in EPS versus $2.01 expected and $2.18 billion in revenue versus $2.13 billion forecast; institutional investors own 88.89% of its shares.

Zimmer Biomet (NYSE:ZBH - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

ZBH has been the subject of a number of other research reports. Sanford C. Bernstein lifted their price target on Zimmer Biomet from $91.00 to $93.00 and gave the stock a "market perform" rating in a report on Thursday, August 6th. Barclays upgraded Zimmer Biomet to a "hold" rating in a research note on Wednesday, October 7th. Citigroup reaffirmed a "neutral" rating on shares of Zimmer Biomet in a research report on Monday, October 5th. Zacks Research upgraded Zimmer Biomet from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 25th. Finally, Weiss Ratings upgraded Zimmer Biomet from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, September 14th. Seven analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Zimmer Biomet presently has a consensus rating of "Hold" and a consensus price target of $104.47.

Zimmer Biomet Trading Down 3.0%

Zimmer Biomet stock opened at $94.54 on Friday. The firm has a 50-day moving average of $94.86 and a 200-day moving average of $91.70. Zimmer Biomet has a one year low of $79.12 and a one year high of $103.70. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The company has a market cap of $18.03 billion, a price-to-earnings ratio of 23.00, a P/E/G ratio of 2.34 and a beta of 0.49.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The business's quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities analysts expect that Zimmer Biomet will post 8.54 earnings per share for the current fiscal year.

Insider Transactions at Zimmer Biomet

In other news, insider Chad F. Phipps sold 3,000 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the transaction, the insider owned 65,231 shares in the company, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The SEC filing for this sale provides additional information. 1.28% of the stock is currently owned by corporate insiders.

Institutional Trading of Zimmer Biomet

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Zimmer Biomet in the second quarter worth $1,344,282,000. State Street Corp raised its holdings in shares of Zimmer Biomet by 0.6% during the second quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider's stock valued at $766,343,000 after purchasing an additional 52,044 shares during the period. Primecap Management Co. CA acquired a new position in shares of Zimmer Biomet during the second quarter valued at about $328,578,000. Dimensional Fund Advisors LP raised its holdings in shares of Zimmer Biomet by 1.1% during the first quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider's stock valued at $201,082,000 after purchasing an additional 24,208 shares during the period. Finally, Bank of America Corp DE bought a new position in shares of Zimmer Biomet during the 2nd quarter worth about $187,480,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.